
MEDLINE INC-CL A
MDLNNASDAQTrading Snapshot
- Day Range
- $309.54 โ $314.47
- 52-Week Range
- $32.82 โ $50.88
- Volume
- $3.46B
- Avg Volume
- $4.11B
- Shares Outstanding
- 1.31B
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $28.43B
- Last Q Revenue
- $7.68B
- P/E Ratio
- 64.1
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.84
- Dividend Yield
- โ
Why Investors Own MDLN
- โHigh-growth profile โ revenue up +17.8% YoY with expanding US Equity exposure.
- โHealthy economics โ 79% gross margin and 23% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MEDLINE INC-CL A
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34
Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.
TD Cowen Maintains Buy on Medline, Lowers Price Target to $45
TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.
RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46
RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.
Truist Securities Maintains Buy on Medline, Lowers Price Target to $47
Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $56 to $47.
Evercore ISI Group Maintains Outperform on Medline, Lowers Price Target to $39
Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $39.
Stifel Maintains Buy on Medline, Lowers Price Target to $45
Stifel analyst Rick Wise maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $50 to $45.